Skip to main content
. Author manuscript; available in PMC: 2014 Jun 1.
Published in final edited form as: Biol Blood Marrow Transplant. 2013 Mar 21;19(6):10.1016/j.bbmt.2013.03.001. doi: 10.1016/j.bbmt.2013.03.001

Figure 2. Overall survival after DLI according to initial CD3+ cell dose and disease risk category.

Figure 2

Low risk included CML-CP and CLL, MM, low-risk lymphomas. High risk included high risk myeloid malignancies (AML, MDS, CML –AP/BC), myelofibrosis, myeloproliferative disorders, and high risk lymphoid malignancies (ALL, High grade lymphomas (Hodgkin lymphoma, diffuse large B cell lymphoma, transformed non-Hodgkin lymphoma)).

a. Low risk category. 1- and 3-year overall survival were 94% and 73% for cell dose A, 67% and 53% for cell dose B and 60% and 55% for cell dose C (P =0.07).

b. High risk category. 1- and 3-year overall survival were 47% and 27% for cell dose A, 60% and 42% for cell dose B and 41% and 22% for cell dose C (P =0.35)